| Original language | English (US) |
|---|---|
| Pages (from-to) | 387 |
| Number of pages | 1 |
| Journal | JAMA cardiology |
| Volume | 6 |
| Issue number | 4 |
| DOIs |
|
| State | Published - Apr 2021 |
Funding
reported grants from National Institutes of Health to Northwestern University during the conduct of the study; personal fees for consulting for Amgen, AstraZeneca, Avidity, Pfizer, Janssen, and Cytokinetics and advisory board participation with Invitae, Tenaya Therapeutics, and Exonics; and grants from National Institutes of Health and the Department of Defense to Northwestern University outside the submitted work. Dr McNally is also a founder of Ikaika Therapeutics outside the submitted work. No other disclosures were reported.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine